# Real-World Evidence Conference

Conference | October 24-25

## PROGRAM COMMITTEE CHAIR

**David Martin, MD, MPH**
Vice President, Head, PCO Center of Excellence
Novartis

## PROGRAM COMMITTEE

**Jaclyn Bosco, PhD, MPH, FISPE**
Vice President and Global Head of Epidemiology
IQVIA

**John Concato, MD, MPH, MS**
Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA

**Diane Gubernot, DrPH, MPH**
Epidemiologist, CBER
FDA

**Rachele Hendricks-Sturrup, DrSc, MA, MSc**
Research Director, Real-World Evidence, Duke-Robert J. Margolis, MD, Center for Health Policy

**Charles Lee, MBA, MS**
Executive Regulatory Science Director
AstraZeneca

**Sarah Martin, PhD, MS**
Senior Director - Global Regulatory Policy (Oncology)
Eli Lilly & Co.

**Brittany Avin McKelvey, PhD**
Director, Regulatory Affairs
Friends of Cancer Research

**Keri Monda, PhD, MS**
Executive Director, Center for Observational Research
Amgen

## Overview

In an ever-evolving healthcare landscape, real-world evidence (RWE) has emerged as a pivotal tool for shaping regulatory and reimbursement decisions. Traditionally associated with post-market safety monitoring, RWE now plays a critical role throughout the entire product development lifecycle. It enables real-time data analysis to enhance our understanding of diseases, refine treatment approaches, and substantiate coverage decisions.

DIA's *Real-World Evidence Conference* is designed to delve into the latest advancements and innovative applications of RWE. This conference will provide participants with cutting-edge insights into how RWE is transforming drug development and regulatory practices. By exploring new methodologies, technological advancements, and practical case studies, the event will equip attendees with the knowledge and tools necessary to leverage RWE effectively and drive forward healthcare decision-making. Don't miss this opportunity to stay ahead in the field and harness RWE's full potential to impact patient outcomes and policy.

## Event Goals and Offerings

- Gain a comprehensive understanding of the latest advancements and regulatory updates in RWE from leading experts in the field
- Engage with industry leaders, regulatory authorities, and peers to discuss innovative strategies and practical applications in RWE
- Explore diverse use cases and methodological insights across early development, late-phase, and post-marketing scenarios to enhance your knowledge and practice
- Discover cutting-edge technologies and operational strategies that are shaping the future of RWE generation
- Examine the intersection of AI and RWE, and discuss the implications for policy and regulatory frameworks

## Why You Can't Miss It

- Stay at the forefront of real-world evidence (RWE) with the latest advancements, regulatory updates, and practical applications from leading experts and key industry players
- Deep dive into various stages of drug development, from early-phase studies to post-marketing safety, and understand how RWE is applied across different use cases
- Learn about the latest methodological approaches and innovations in RWE, including causal methods, negative control outcomes, and sensitivity analyses
- Discover new technologies and operational strategies that enhance RWE generation, such as AI-enabled data abstraction and data linkage techniques
- Explore strategies to address health equity and improve diversity in drug development, leveraging RWE to build more representative and inclusive study populations
- Gain insights into international regulatory perspectives and practical challenges in using RWE, and learn how to balance data innovation with scientific rigor
- Understand how artificial intelligence is transforming clinical study designs and policy frameworks, and explore the future intersection of AI and RWE in pharmacoepidemiology

| DAY ONE \| THURSDAY, OCTOBER 24 | | ROOM |
|---|---|---|
| 7:30AM-5:15PM | Conference Registration | Liberty Ballroom Foyer (Ballroom Level) |
| 7:30-8:30 AM | Networking Breakfast | Liberty Ballroom A |
| 8:30-8:45AM | Opening Remarks | Liberty Ballroom B |
| 8:45-9:45AM | **Session 1:** A Year in Review | Liberty Ballroom B |
| 9:45-10:30AM | Refreshment and Networking Break | Liberty Ballroom A |
| 9:55–10:25AM | Hosted Session/Non-CE: **Case Study Spotlight hosted by OM1:** Elevate Your Real-World Evidence Without Stretching Your Resources | Salon 5/6 (Mezzanine Level) |
| 10:30-11:45AM | **Session 2:** Early Development Use Cases | Liberty Ballroom B |
| 11:45AM-12:45PM | Networking Luncheon | Liberty Ballroom A |
| 12:45-2:00PM | **Session 3:** RWD Innovations in Late Phase and Postmarket Settings: A Review of Use Cases | Liberty Ballroom B |
| 2:10-3:25PM | **Session 4:** Real-World Data Standards for Regulatory Submissions: Exploring the Challenges, Solutions, and Potential Alternatives | Liberty Ballroom B |
| 3:25-4:00PM | Refreshment and Networking Break | Liberty Ballroom A |
| 4:00-5:15PM | **Session 5:** Health Equity in Drug Development: Leveraging RWD to Inform and Improve Diversity | Liberty Ballroom B |
| 5:15-6:15PM | Networking Reception | Liberty Ballroom A |
| **DAY TWO \| FRIDAY, OCTOBER 25** | | **ROOM** |
| 7:30AM-4:10PM | Conference Registration | Liberty Ballroom Foyer (Ballroom Level) |
| 7:30-8:00AM | Networking Breakfast | Liberty Ballroom A |
| 8:00-9:15AM | **Opening Remarks and Session 6:** Sand in Your Shoes? The Nitty-Gritty in Generating Regulatory-Grade RWE Using Emerging Data Sources and New Platforms: Global Perspectives | Liberty Ballroom B |
| 9:20-10:35AM | **Session 7:** Methodological Insights on Aspects of Non-Interventional Studies | Liberty Ballroom B |
| 10:35-11:15AM | Refreshment and Networking Break | Liberty Ballroom A |
| 10:40-11:10AM | Hosted Session/Non-CE: **Case Study Spotlight hosted by Parexel:** Transforming Evidence Generation: Scalable Solutions for Complex Requirements | Salon 5/6 (Mezzanine Level) |
| 11:15AM-12:30PM | **Session 8:** Innovations in Technology and Operational Excellence | Liberty Ballroom B |
| 12:30-1:30PM | Networking Luncheon | Liberty Ballroom A |
| 1:30-3:00PM | **Session 9:** Is the Future Here, Near, or Neither? Exploring the Intersection of AI and RWD in Pharmacoepidemiology | Liberty Ballroom B |
| 3:00-4:00PM | Looking Forward and Closing Remarks | Liberty Ballroom B |
| 4:00PM | Conference Adjourns | |

## Learning Objectives

At the conclusion of this conference, participants should be able to:

- Identify the new key milestones and significant advancements in real-world evidence (RWE) since last year
- Determine how RWE is used across different stages of drug development
- Identify advanced methodological approaches for generating RWE, including causal methods, negative control outcome studies, and sensitivity analyses, to improve the design and validity of non-interventional studies
- Evaluate the latest technological innovations and operational strategies, such as AI-enabled data abstraction and data linkage methods, to enhance the quality and efficiency of RWE generation
- Discuss how to leverage RWE to address health equity and improve diversity in drug development
- Examine international regulatory perspectives and practical challenges in applying RWE
- Assess the role of artificial intelligence in transforming clinical study designs, optimizing patient selection, and shaping policy frameworks to integrate AI with RWE effectively

## Continuing Education Credits

Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This program is designated for up to 12.5 contact hours or 1.25 continuing education units (CEU's). Type of Activity: Knowledge.

DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy requested CEUs through the CPE Monitor system. **All ACPE-certified activity credit requests need to be submitted through DIA's My Transcript within 45-days post activity.** If ACPE credit is not requested by Friday, November 29, the CEU request will not be transmitted through to the CPE Monitor. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net

**ACPE CREDIT REQUESTS MUST BE SUBMITTED BY FRIDAY, NOVEMBER 29, 2024.**

## Continuing Education Credit Allocation

**October 24 Day 1: Real World Evidence Conference:** 6 contact hours or .6 CEUs Type of Activity: Knowledge, 0286-0000-24-071-L04-P

**October 25 Day 2: Real World Evidence Conference:** 6.25 contact hours or .625 CEUs Type of Activity: Knowledge, 0286-0000-24-072-L04-P

## Continuing Legal Education

For attorneys who would like to receive continuing legal education credits for attending The 2024 A Real-World Evidence Conference, please complete your state's application for credit and submit accordingly. If you require additional information, please contact CE@DIAglobal.org.

## Statement of Credit

If you would like to receive a statement of credit for the days you attend the conference, you must attend one or both days of the conference, in their entirety, sign in at the DIA registration desk upon arrival, and request CE credit online through My Transcript (see instructions below). Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests beginning **Friday, November 8, 2024.**

**If you are claiming CE credit for the conference you must:**

1. Attend one or both days of the conference, (in their entirety)
2. Sign in at the DIA registration desk each day, upon arrival
3. Access your DIA account and select My Transcript to claim your CE credit, available on **Friday, November 8, 2024**
4. **ACPE credit must be submitted by Friday, November 29, 2024**

## DIA Disclosure Policy

It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any relevant financial relationships related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosures will be included in the handout materials.

This educational activity may include references to the use of products for indications not approved by the FDA. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the DIA or any of the manufacturers of products mentioned herein. Faculty for this educational activity was asked to disclose any discussion of unlabeled or unapproved uses of drugs or medical devices.
Disclosure statements are included with each speaker's biographical sketch. The faculty who reported relevant financial relationships with ineligible entities related to the educational content of this CE activity have been mitigated.

DIA staff members have no relevant financial relationships to disclose. To view DIA's Disclosure and Grievance Policies, visit **DIAglobal.org/CE**

TO ACCESS MY TRANSCRIPT:

- Visit **DIAglobal.org**
- **Sign In** with your DIA User ID and Password
- Select the **Welcome Menu** in the upper right hand corner (where your name appears)
- Select **My Account** from the menu
- Select **My Transcripts** then **Manage My Transcripts**

ACCESS PRESENTATIONS:

- Visit **DIAglobal.org**
- **Sign In** with your DIA User ID and Password
- Select the **Welcome Menu** in the upper right hand corner (where your name appears)
- Select **My Account** from the menu
- Choose **My Presentation**

Please Note: DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder. **Presentations will be available for six months post conference.*

## Want to view the detailed agenda? Download DIA's Mobile App!

- Agenda at your fingertips
- Network with Attendees, Speakers, Exhibitors
- Ask questions live during sessions through the session chat function




You will be directed to login to our My DIA Account in order to access the mobile app.

Follow the instructions on screen, or please see the registration desk/contact NAEvents@DIAglobal.org if you need additional assistance.